Sovremennye podkhody k farmakoterapii bolezni Parkinsona: terapiya motornykh simptomov - gipokineziya, rigidnost' i tremor
- Autores: Pizova N.V1
-
Afiliações:
- Edição: Nº 10 (2014)
- Páginas: 8-11
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/287015
- ID: 287015
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
The paper presents the main ways for the treatment of patients with Parkinson's disease. Particular attention is paid to the modern approaches to pharmacotherapy of motor symptoms - hypokinesia, rigidity and tremor, as a crucial for this disease. Substitution (symptomatic) therapy promotes restoration of dopamine deficiency in the brain, and thereby improves the functional state of the patients. The results of international studies of pharmacotherapy of motor symptoms are presented, and different therapeutic strategies are considered.
Palavras-chave
Texto integral
Bibliografia
- Chaudhuri K.R., Healy D.G., Schapira A.H.V. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet. Neurology. 2006;5(3):235-45.
- Hall E.D., Andrus P.K., Oostveen J.A. Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons. Brain Res. 1996;742( 1 -2):80-8.
- Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs. levodopa on Parkinson disease progression. JAMA. 2002;287:1653-61.
- Артемьев Д.В. Современные принципы терапии болезни Паркинсона. Трудный пациент. 2005;3(12):10-5.
- Иллариошкин С.Н. Основные принципы терапии болезни Паркинсона. Рос. мед. журн. 2004;12(10):604-08.
- Fox S.H., Katzenschlager R., Lim S.Y., et al. The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the motor symptoms of Parkinson's disease. Mov. Disord. 2011;26(3):2-4.
- Fahn S. The history of dopamine and levodopa in the treatment of Parkinson's disease. Mov. Disord. 2008;23(3):497-508.
- Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol. 2004;61(4):561-66.
- Goetz C.G., Poewe W., Rascol O., Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov. Disord. 2005;20(5):523-39.
- Adler C.H., Singer C., O'Brien C., et al. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III. Arch Neurol. 1998;55(8):1089-95.
- Deane K.H., Spieker S., Clarke C.E. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst. Rev. 2004;(4):CD004554.
- Fahn S., Oakes D., Shoulson I., et al. Levodopa and the progression of Parkinson's disease. N. Engl. J. Med. 2004;351 (24):2498-508.
- Talati R., Baker W.L., Patel A.A., Reinhart K., Coleman C.I. Adding a dopamine agonist to preexisting levodopa therapy vs levodopa therapy alone in advanced Parkinson's disease: a meta analysis. Int. J. Clin. Pract. 2009;63(4):613-23.
- Kvernmo T., Houben J., Sylte I. Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med. Chem. 2008;8(12):1049-67.
- Hauser R.A., Rascol O., Korczyn A.D. et al. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov. Disord. 2007;22( 16):2409-17.
- Иллариошкин С.Н. Терапия паркинсонизма: возможности и перспективы. Cons Med. 2009;1:35-40. Прил. Неврология.
- Navan P., Findley L.J., Jeffs J.A.R., et al. Doubleblind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease. Mov. Dis. 2003:18:176-80.
- Rascol O. Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release. Eur. J. Neurol. 2011;18(1):3-10.
- Olanow C.W., Watkins P.B. Tolcapone: an efficacy and safety review. Clin. Neuropharmacol. 2007;30(5):287-94.
- Reichmann H., Boas J., Macmahon D., et al. Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations. Acta Neurol. Scand. 2005;111(1):21-8.
- Шток В.Н. и др. Экстрапирамидные расстройства. М., 2002. 608 с.
- Snow B.J., Macdonald L., Mcauley D., Wallis W. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study. Clin. Neuropharmacol. 2000;23(2):82-5.
- Luginger E., Wenning G.K., Bosch S., Poewe W. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease. Mov. Disord. 2000;15(5):873-78.
- Rascol O., Dubois B., Caldas A.C., et al. Early piribedil monotherapy of Parkinson's disease: a planned seven-month report of the REGAIN study. Mov. Disord. 2006;21(12): 2110-15.
Arquivos suplementares
